Today: 29 June 2026
Browse Category

NASDAQ:AXSM 3 November 2025 - 2 January 2026

AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation

AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation

Axsome Therapeutics shares surged 22.9% to $182.64 on Dec. 31 after the FDA accepted its AXS-05 filing for Alzheimer’s disease agitation and set an April 30, 2026 target action date. The company also said it plans to submit an NDA for AXS-12 in narcolepsy in January, following supportive FDA meeting minutes. Trading volume reached 3.1 million shares.
2 January 2026
·
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics shares surged 23% to $182.64 after the FDA accepted its supplemental application for AXS-05 in Alzheimer’s agitation and granted priority review. The stock traded on heavy volume, swinging between $148.79 and $184.40. Axsome also said its AXS-12 narcolepsy drug remains on track for a January 2026 filing. Markets will reopen Friday after the New Year’s Day holiday.
1 January 2026
···
Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

Axsome Therapeutics shares surged 22.9% to $182.64 after the FDA granted priority review to its application for AXS-05 in treating agitation in Alzheimer’s disease, setting an April 30 decision date. The company also plans to file for approval of AXS-12 for cataplexy in narcolepsy this month, following supportive FDA meeting minutes. Trading volume reached 3.1 million shares.
1 January 2026
··
AXSM Stock Today (Nov. 25, 2025): Axsome Therapeutics Near Record Highs on 63% Revenue Surge

AXSM Stock Today (Nov. 25, 2025): Axsome Therapeutics Near Record Highs on 63% Revenue Surge

Axsome Therapeutics shares closed at $151.20 on Monday, near record highs, after reporting 63% year-over-year revenue growth in Q3 2025 to $171 million. The stock has climbed over 50% in the past year, valuing the company at about $7.6 billion. Net loss for the quarter narrowed to $47.2 million, or –$0.94 per share. Trading volume on Monday was roughly 540,000 shares.
25 November 2025
·

Stock Market Today

  • IMF Research Questions Bonds as Safe Havens in Stock Market Crashes, Suggests Commodities ETFs
    June 28, 2026, 10:12 PM EDT. Recent IMF research reveals that bonds may no longer serve as reliable diversifiers during stock market downturns due to increased positive correlation with stocks since 2019. Traditional wisdom that bonds rise when stocks fall is challenged. Instead, adding commodities like precious metals could offer better portfolio protection. ETFs such as iShares Silver Trust (SLV), which tracks silver bullion and has returned 21.75% annually over five years, and VanEck Rare Earth and Strategic Metals ETF (REMX) provide exposure to these assets. Silver's sharp 147.9% gain in 2025 reflects inflation concerns and industrial demand but also comes with volatility, having dropped 50% since its January peak. Investors should weigh risks carefully when seeking diversification beyond stocks and bonds.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop